An fMRI Study of Ketamine in Treatment-Resistant Depression
ID Number 08-0874Principal Investigator(s)
Department(s) or Division(s)
Mood and Anxiety Disorders Program - MAP
The purpose of this study is to investigate the antidepressant mechanism of action of ketamine in patients with treatment-resistant major depression (TRD) using functional magnetic resonance imaging (fMRI). Ketamine is a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist that has demonstrated rapid-acting antidepressant properties after a single intravenous (IV) infusion in patients with treatment-resistant major depression (TRD).The neurobiological mechanisms of the antidepressant effects of ketamine are unknown and represent a critical area of research in the pathophysiology and treatment of major depression.
Recruiting Patients: Yes